Drug Trial Radar · NCT00552526
Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy
Last checked: Nov 19, 2026Latest source record: Mar 19, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 2007
Primary completion
Jan 2011
Study completion Dec 2013
Sponsor
- Lead sponsor
- Oslo University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 2, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open randomized controlled study in children with mental retardation and refractory epilepsy in which treatment with ketogenic diet (KD) is compared with treatment with the antiepileptic drug (AED), not tried by the patient before, which we consider to be the most appropriate AED for the patient.
Conditions
- Epilepsy
- Mental Retardation
Interventions
Ketogenic dietDietary supplement
Ketogenic diet is a very strict high fat diet
Antiepileptic drug (AED)Drug
An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparing amount of patients with 100%, >90% and >50% reduction in number of seizures between the two groups of seizuresTime frame: 4 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SSE, Nevrological dep. , Rikshospitalet University hospital
Oslo, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.